Near Infrared Light Treatment Reduces Synaptic Levels of Toxic Tau Oligomers in Two Transgenic Mouse Models of Human Tauopathies.


Journal

Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963

Informations de publication

Date de publication:
May 2019
Historique:
received: 08 05 2018
accepted: 15 07 2018
pubmed: 19 8 2018
medline: 21 8 2019
entrez: 19 8 2018
Statut: ppublish

Résumé

Tau oligomers are emerging as a key contributor to the synaptic dysfunction that drives cognitive decline associated with the clinical manifestation and progression of Alzheimer's disease (AD). Accordingly, there is ample consensus that interventions that target tau oligomers may slow or halt the progression of AD. With this ultimate goal in mind, in the present study, we investigated tau oligomer accumulation and its synaptic and behavioral consequences after an in vivo treatment with near infrared (NIR) light (600-1000 nm) in two transgenic mouse models, overexpressing human tau either alone (hTau mice) or in combination with amyloid beta (3xTgAD mice). We found that a 4-week exposure to NIR light (90 s/day/5 days a week) significantly reduced levels of endogenous total and oligomeric tau in both synaptosomes and total protein extracts from the hippocampus and cortex of hTau mice and improved deteriorating memory function. Similar results were observed in the 3xTgAD mice, which further displayed reduced synaptic Aβ after NIR light treatment. On the other hand, ex vivo binding of tau oligomers in isolated synaptosomes as well as tau oligomer-induced depression of long-term potentiation (LTP) in hippocampal slices from NIR light-treated wt mice were unaffected. Finally, levels of proteins critically involved in two mechanisms associated with clearance of misfolded tau, inducible HSP70 and autophagy, were upregulated in NIR light treated mice. Collectively, these results show that NIR light decreases levels of endogenous toxic tau oligomers and alleviate associated memory deficits, thus furthering the development of NIR light as a possible therapeutic for AD.

Identifiants

pubmed: 30120733
doi: 10.1007/s12035-018-1248-9
pii: 10.1007/s12035-018-1248-9
pmc: PMC6476871
doi:

Substances chimiques

Amyloid beta-Peptides 0
Biomarkers 0
HSP70 Heat-Shock Proteins 0
tau Proteins 0

Types de publication

Journal Article

Langues

eng

Pagination

3341-3355

Subventions

Organisme : NIA NIH HHS
ID : R01 AG042890
Pays : United States
Organisme : NIA NIH HHS
ID : 5R01AG042890
Pays : United States

Références

Neurobiol Dis. 2000 Apr;7(2):87-98
pubmed: 10783293
Curr Biol. 2001 Oct 16;11(20):1569-77
pubmed: 11676916
Science. 2002 Oct 25;298(5594):789-91
pubmed: 12399581
Science. 2003 Apr 18;300(5618):486-9
pubmed: 12702875
Neurology. 2003 May 13;60(9):1495-500
pubmed: 12743238
J Neurochem. 2003 Aug;86(3):582-90
pubmed: 12859672
Neuron. 2003 Jul 31;39(3):409-21
pubmed: 12895417
Neurosci Res. 2006 Mar;54(3):197-201
pubmed: 16406150
J Neurosci. 2007 Mar 14;27(11):2866-75
pubmed: 17360908
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Ann Neurol. 1991 Oct;30(4):572-80
pubmed: 1789684
Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15997-6002
pubmed: 18832465
Cell. 2010 Feb 5;140(3):313-26
pubmed: 20144757
Photomed Laser Surg. 2010 Apr;28(2):159-60
pubmed: 20374017
Neuroscience. 2010 Aug 11;169(1):516-31
pubmed: 20434528
J Neurosci Res. 2010 Oct;88(13):2923-32
pubmed: 20544830
Biochemistry. 2010 Nov 30;49(47):10039-41
pubmed: 21047142
J Alzheimers Dis. 2011;23(3):521-35
pubmed: 21116053
Acta Neuropathol. 1990;80(2):111-7
pubmed: 2117840
Mol Neurodegener. 2011 Jun 06;6:39
pubmed: 21645391
Biochem Pharmacol. 2011 Oct 15;82(8):931-42
pubmed: 21763291
FASEB J. 2012 May;26(5):1946-59
pubmed: 22253473
FASEB J. 2013 Apr;27(4):1450-9
pubmed: 23271055
J Photochem Photobiol B. 2013 Jun 5;123:13-22
pubmed: 23603448
Neuron. 2013 Sep 4;79(5):887-902
pubmed: 24012003
Biochim Biophys Acta. 2014 Aug;1842(8):1219-31
pubmed: 24071439
Alzheimers Res Ther. 2013 Oct 29;5(5):53
pubmed: 24171818
Alzheimers Res Ther. 2014 Jan 03;6(1):2
pubmed: 24387311
J Alzheimers Dis. 2014;40 Suppl 1:S97-S111
pubmed: 24603946
Neuron. 2014 Jun 18;82(6):1271-88
pubmed: 24857020
J Cell Commun Signal. 2014 Dec;8(4):293-310
pubmed: 25208934
Trends Neurosci. 2014 Dec;37(12):721-32
pubmed: 25223701
Acta Neuropathol Commun. 2014 Oct 21;2:146
pubmed: 25330988
Neurotherapeutics. 2015 Jan;12(1):94-108
pubmed: 25421002
Lancet Neurol. 2015 Apr;14(4):388-405
pubmed: 25792098
J Neurosci. 2015 Oct 21;35(42):14234-50
pubmed: 26490863
J Neurosci Methods. 2016 Mar 1;261:128-34
pubmed: 26774027
Sci Rep. 2016 Jan 20;6:19393
pubmed: 26786552
PLoS Biol. 2016 Jun 02;14(6):e1002472
pubmed: 27254664
Cell Chem Biol. 2016 Aug 18;23(8):992-1001
pubmed: 27499529
Nat Commun. 2017 May 11;8:15295
pubmed: 28492240
J Alzheimers Dis. 2017;59(4):1415-1426
pubmed: 28759972
EMBO J. 2017 Nov 2;36(21):3120-3138
pubmed: 28864542
Sci Rep. 2017 Nov 8;7(1):15012
pubmed: 29118388
ACS Chem Biol. 2018 Mar 16;13(3):636-646
pubmed: 29300447
Elife. 2018 Jul 10;7:
pubmed: 29988016

Auteurs

Michele M Comerota (MM)

University of Texas Medical Branch, 301 University Blvd., Galveston, TX, 77555-1045, USA.

Batbayar Tumurbaatar (B)

University of Texas Medical Branch, 301 University Blvd., Galveston, TX, 77555-1045, USA.

Balaji Krishnan (B)

University of Texas Medical Branch, 301 University Blvd., Galveston, TX, 77555-1045, USA.

Rakez Kayed (R)

University of Texas Medical Branch, 301 University Blvd., Galveston, TX, 77555-1045, USA.

Giulio Taglialatela (G)

University of Texas Medical Branch, 301 University Blvd., Galveston, TX, 77555-1045, USA. gtaglial@utmb.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH